261 related articles for article (PubMed ID: 29668893)
1. Therapeutic Drug Monitoring Guides the Management of Crohn's Patients with Secondary Loss of Response to Adalimumab.
Restellini S; Chao CY; Lakatos PL; Aruljothy A; Aziz H; Kherad O; Bitton A; Wild G; Afif W; Bessissow T
Inflamm Bowel Dis; 2018 Jun; 24(7):1531-1538. PubMed ID: 29668893
[TBL] [Abstract][Full Text] [Related]
2. Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases.
Gonczi L; Kurti Z; Rutka M; Vegh Z; Farkas K; Lovasz BD; Golovics PA; Gecse KB; Szalay B; Molnar T; Lakatos PL
BMC Gastroenterol; 2017 Aug; 17(1):97. PubMed ID: 28789636
[TBL] [Abstract][Full Text] [Related]
3. Comparative Effectiveness of Infliximab Versus Adalimumab in Patients with Biologic-Naïve Crohn's Disease.
Benmassaoud A; Al-Taweel T; Sasson MS; Moza D; Strohl M; Kopylov U; Paradis-Surprenant L; Almaimani M; Bitton A; Afif W; Lakatos PL; Bessissow T
Dig Dis Sci; 2018 May; 63(5):1302-1310. PubMed ID: 29243105
[TBL] [Abstract][Full Text] [Related]
4. Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study.
Otake H; Matsumoto S; Mashima H
Medicine (Baltimore); 2017 Apr; 96(16):e6635. PubMed ID: 28422861
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of patients with Crohn's disease who received infliximab or adalimumab as the first-line biologics.
Inokuchi T; Takahashi S; Hiraoka S; Toyokawa T; Takagi S; Takemoto K; Miyaike J; Fujimoto T; Higashi R; Morito Y; Nawa T; Suzuki S; Nishimura M; Inoue M; Kato J; Okada H
J Gastroenterol Hepatol; 2019 Aug; 34(8):1329-1336. PubMed ID: 30724387
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.
Kelly OB; Donnell SO; Stempak JM; Steinhart AH; Silverberg MS
Inflamm Bowel Dis; 2017 Jul; 23(7):1202-1209. PubMed ID: 28498155
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of infliximab after loss of response of/intolerance to adalimumab in pediatric Crohn's disease: A retrospective multicenter cohort study of the "GETAID pédiatrique".
Lecoutour A; Dupont C; Caldari D; Dumant C; Vanrenterghem A; Ruiz M; Duclaux-Loras R; Berthet S; Dimitrov G; Lacroix D; Duvant P; Roman C; Wagner AC; Bourmaud A; Viala J; Ruemmele FM; Pigneur B;
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1116-1125. PubMed ID: 38314896
[TBL] [Abstract][Full Text] [Related]
8. Adalimumab dose escalation is effective and well tolerated in Crohn's disease patients with secondary loss of response to adalimumab.
Duveau N; Nachury M; Gerard R; Branche J; Maunoury V; Boualit M; Wils P; Desreumaux P; Pariente B
Dig Liver Dis; 2017 Feb; 49(2):163-169. PubMed ID: 27899263
[TBL] [Abstract][Full Text] [Related]
9. Proactive Therapeutic Drug Monitoring of Adalimumab Is Associated With Better Long-term Outcomes Compared With Standard of Care in Patients With Inflammatory Bowel Disease.
Papamichael K; Juncadella A; Wong D; Rakowsky S; Sattler LA; Campbell JP; Vaughn BP; Cheifetz AS
J Crohns Colitis; 2019 Aug; 13(8):976-981. PubMed ID: 30689771
[TBL] [Abstract][Full Text] [Related]
10. Circulating Interleukin 6 and Albumin, and Infliximab Levels Are Good Predictors of Recovering Efficacy After Dose Escalation Infliximab Therapy in Patients with Loss of Response to Treatment for Crohn's Disease: A Prospective Clinical Trial.
Suzuki Y; Matsui T; Ito H; Ashida T; Nakamura S; Motoya S; Matsumoto T; Sato N; Ozaki K; Watanabe M; Hibi T
Inflamm Bowel Dis; 2015 Sep; 21(9):2114-22. PubMed ID: 26218144
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a concomitant elemental diet to reduce the loss of response to adalimumab in patients with intractable Crohn's disease.
Sugita N; Watanabe K; Kamata N; Yukawa T; Otani K; Hosomi S; Nagami Y; Tanaka F; Taira K; Yamagami H; Tanigawa T; Shiba M; Watanabe T; Tominaga K; Kabata D; Shintani A; Arakawa T; Fujiwara Y
J Gastroenterol Hepatol; 2018 Mar; 33(3):631-637. PubMed ID: 28857255
[TBL] [Abstract][Full Text] [Related]
12. Does weight-adjusted anti-tumour necrosis factor treatment favour obese patients with Crohn's disease?
Bhalme M; Sharma A; Keld R; Willert R; Campbell S
Eur J Gastroenterol Hepatol; 2013 May; 25(5):543-9. PubMed ID: 23337170
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Drug Monitoring Increases Drug Retention of Anti-Tumor Necrosis Factor Alpha Agents in Pediatric Patients With Crohn's Disease.
Gofin Y; Matar M; Shamir R; Assa A
Inflamm Bowel Dis; 2020 Jul; 26(8):1276-1282. PubMed ID: 31634402
[TBL] [Abstract][Full Text] [Related]
14. Benefit of infliximab reintroduction after successive failure of infliximab and adalimumab in Crohn's disease.
Gagniere C; Beaugerie L; Pariente B; Seksik P; Amiot A; Abitbol V; Allez M; Cosnes J; Sokol H
J Crohns Colitis; 2015 Apr; 9(4):349-55. PubMed ID: 25547977
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab trough serum levels and anti-adalimumab antibodies in the long-term clinical outcome of patients with Crohn's disease.
Bodini G; Giannini EG; Savarino V; Del Nero L; Pellegatta G; De Maria C; Baldissarro I; Savarino E
Scand J Gastroenterol; 2016 Sep; 51(9):1081-6. PubMed ID: 27207330
[TBL] [Abstract][Full Text] [Related]
16. One-Year Clinical Outcomes in an IBD Cohort Who Have Previously Had Anti-TNFa Trough and Antibody Levels Assessed.
Tighe D; Hall B; Jeyarajah SK; Smith S; Breslin N; Ryan B; McNamara D
Inflamm Bowel Dis; 2017 Jul; 23(7):1154-1159. PubMed ID: 28486256
[TBL] [Abstract][Full Text] [Related]
17. [Frequency and possible reasons for the loss of response to biological therapy in Crohn's disease after a one-year treatment period].
Molnár T; Farkas K; Nyári T; Szepes Z; Nagy F; Kiss T; Wittmann T
Orv Hetil; 2011 Jun; 152(24):951-7. PubMed ID: 21609921
[TBL] [Abstract][Full Text] [Related]
18. Elective switching from infliximab to adalimumab in stable Crohn's disease.
Hoentjen F; Haarhuis BJ; Drenth JP; de Jong DJ
Inflamm Bowel Dis; 2013; 19(4):761-6. PubMed ID: 23446337
[TBL] [Abstract][Full Text] [Related]
19. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
[No Abstract] [Full Text] [Related]
20. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring.
Assa A; Matar M; Turner D; Broide E; Weiss B; Ledder O; Guz-Mark A; Rinawi F; Cohen S; Topf-Olivestone C; Shaoul R; Yerushalmi B; Shamir R
Gastroenterology; 2019 Oct; 157(4):985-996.e2. PubMed ID: 31194979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
